Headlands Technologies LLC Invests $51,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Headlands Technologies LLC purchased a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 186 shares of the medical research company’s stock, valued at approximately $51,000.

Several other institutional investors have also bought and sold shares of BIO. Capital Advisors Ltd. LLC lifted its stake in shares of Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after acquiring an additional 62 shares during the period. Sound Income Strategies LLC bought a new position in Bio-Rad Laboratories during the 1st quarter valued at $38,000. Principal Securities Inc. acquired a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $41,000. EntryPoint Capital LLC bought a new stake in shares of Bio-Rad Laboratories in the 1st quarter worth $51,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Bio-Rad Laboratories by 36.8% in the fourth quarter. Parallel Advisors LLC now owns 171 shares of the medical research company’s stock valued at $55,000 after buying an additional 46 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Activity at Bio-Rad Laboratories

In related news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP James Barry sold 623 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Stock Up 1.3 %

Shares of Bio-Rad Laboratories stock opened at $330.33 on Tuesday. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $377.88. The company has a market cap of $9.42 billion, a P/E ratio of -31.89 and a beta of 0.95. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average price of $319.89 and a 200 day moving average price of $307.37.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.99. The firm had revenue of $638.50 million for the quarter, compared to analyst estimates of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company’s revenue for the quarter was down 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.00 EPS. As a group, analysts expect that Bio-Rad Laboratories, Inc. will post 10.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on BIO shares. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target on the stock. Jefferies Financial Group restated a “hold” rating and issued a $315.00 price target (down previously from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $401.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Citigroup increased their price target on Bio-Rad Laboratories from $300.00 to $350.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $358.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.